The stock of Immuneering Corp (IMRX) has gone up by 9.22% for the week, with a 84.44% rise in the past month and a 41.07% rise in the past quarter. The volatility ratio for the week is 13.49%, and the volatility levels for the past 30 days are 6.73% for IMRX. The simple moving average for the past 20 days is 27.88% for IMRX’s stock, with a 28.92% simple moving average for the past 200 days.
Is It Worth Investing in Immuneering Corp (NASDAQ: IMRX) Right Now?
Additionally, the 36-month beta value for IMRX is 0.01. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMRX is 25.96M and currently, short sellers hold a 3.56% ratio of that float. The average trading volume of IMRX on June 17, 2025 was 218.50K shares.
IMRX) stock’s latest price update
Immuneering Corp (NASDAQ: IMRX)’s stock price has plunge by 24.74relation to previous closing price of 1.90. Nevertheless, the company has seen a 9.22% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-16 that CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025.
Analysts’ Opinion of IMRX
Needham, on the other hand, stated in their research note that they expect to see IMRX reach a price target of $15, previously predicting the price at $20. The rating they have provided for IMRX stocks is “Buy” according to the report published on March 15th, 2024.
IMRX Trading at 55.82% from the 50-Day Moving Average
After a stumble in the market that brought IMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.12% of loss for the given period.
Stock Fundamentals for IMRX
The total capital return value is set at -1.41. Equity return is now at value -102.48, with -89.10 for asset returns.
Based on Immuneering Corp (IMRX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -13.13.
Currently, EBITDA for the company is -63.69 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.48.
Conclusion
In conclusion, Immuneering Corp (IMRX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
